Reverse genetic tools and novel models of henipavirus infection10/28/2022 - 09/30/2025 (Co-Investigator)
PI:
Elke Muhlberger, PhDBill and Melinda Gates Foundation
Evaluation of mRNA-based vaccine approaches against endemic coronaviruses12/07/2021 - 09/30/2024 (PI)
Moderna Therapeutics
CFAR Developmental Award: A humanized mouse model to investigate the impact of HIV persistence and antiretroviral treatment on vaccine-induced immune responses07/01/2023 - 06/30/2024 (Subcontract PI)
The Miriam Hospital NIH NIAID2P30AI042853-25
Low-dose RNA vaccine platform for tickborne flaviviruses03/01/2024 - 05/31/2024 (Subcontract PI)
Tiba Biotech LLC NIH NIAID1R43AI165194-01A1
Evaluation of mRNA-based vaccine approaches against DENV03/14/2023 - 05/30/2024 (Multi-PI)
PI:
Florian Douam, PhDModerna Therapeutics
Characterization of a human-specific positive regulator of flavivirus infection04/12/2021 - 03/31/2024 (PI)
NIH/National Institute of Allergy & Infectious Diseases3K22AI144050-02S1
Defining the Impact of Per/Polyfluoroalkyl Substance Exposure on Susceptibility to SARS-CoV-2 Infection and Disease03/02/2021 - 02/29/2024 (Multi-PI)
PI:
Florian Douam, PhDNIH/National Institute of Environmental Health Sciences5R21ES032882-02
Therapeutic effects of NAPc2 in SARS-CoV-2 infection of K18-hACE2 transgenic mice03/15/2021 - 03/31/2022 (Multi-PI)
PI:
Florian Douam, PhDARCA Biopharma, Inc.